Company profile: Eleva Biologics
1.1 - Company Overview
Company description
- Provider of novel biological therapies developed with pharmaceutical partners, leveraging a unique moss-based production platform to produce biologics such as antibodies, replacement enzymes, and fusion toxins; has advanced drug candidates into clinical phases.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eleva Biologics
Alsachim
HQ: France
Website
- Description: Provider of contract research and development services to customers around the world, stable isotope-labeled compounds for pharmaceuticals, environmental studies, and clinical diagnostics, and labeled internal and reference standards for LC-MS/MS analysis to ensure accurate quantification.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Alsachim company profile →
Araris Biotech
HQ: Switzerland
Website
- Description: Provider of proprietary peptide linker technology for efficient payload attachment without antibody engineering, enabling creation of stable, homogenous, highly soluble antibody-drug conjugates (ADCs) with improved therapeutic efficacy and reduced side effects; also offers ADC development using off-the-shelf antibodies to deliver drugs to cancer cells with improved stability and solubility in a cost-effective manner.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Araris Biotech company profile →
BioDot
HQ: United States
Website
- Description: Provider of automated low-volume, non-contact quantitative fluid dispensing systems and lamination, cutting, and assembly expertise. Platforms enable direct dispensing of lines and dots on membranes, papers, microwell plates, slides, and microfluidics, plus web handling and dip coating from roll stock and auto lamination, serving R&D through high-volume manufacturing in industrial, diagnostic, life science, and medical markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioDot company profile →
Axion Biosystems
HQ: United States
Website
- Description: Provider of multi-electrode array and impedance-based platforms for real-time, continuous, label-free cellular analysis, including monitoring of proliferation, viability, morphology, attachment, signaling, and immune cell-mediated killing. Offers single- and multi-well systems, high-throughput formats, automation modules, and integrated circuits to eliminate stimulation artifacts for research, clinical, and drug discovery markets.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Axion Biosystems company profile →
Polyplus Transfection
HQ: France
Website
- Description: Provider of innovative solutions for in vivo, in vitro and ex vivo delivery of nucleic acids for research, bioproduction and therapeutics, including transfection reagents for lentiviral (FectoVIR®-LV) and AAV production (FectoVIR®-AAV), PEIpro® for viral vector bioproduction, in vivo–jetPEI®, LipidBrick® Library for LNP formulation, and in vivo-jetRNA®+ for mRNA/saRNA delivery.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Polyplus Transfection company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eleva Biologics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eleva Biologics
2.2 - Growth funds investing in similar companies to Eleva Biologics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eleva Biologics
4.2 - Public trading comparable groups for Eleva Biologics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →